

Hepatitis C: Epclusa

Member Information

1. Last Name: _____ 2. First Name: _____
3. Trillium ID #: _____ 4. Date of Birth: _____ 5. Gender: _____

Prescriber Information

1. Prescriber Name: _____ 2. NPI #: _____
3. Requestor Name (Nurse/Office Staff): _____
4. Mailing Address: _____ City: _____ State: _____ Zip: _____
5. Phone #: _____ Ext. _____ Fax #: _____

Drug Information

1. Drug Name: Epclusa 2. Strength: _____ 3. Quantity per 30 Days: 28
4. Length of Therapy (in days): 12 Weeks 24 Weeks

Clinical Information

Total Length of Therapy (Check ONE):

12 weeks = Genotype 1, 2, 3, 4, 5, or 6 treatment naïve and treatment experienced without cirrhosis and with compensated cirrhosis (Child Pugh A) or treatment-naïve and treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A)

12 weeks with ribavirin = Genotypes 1,2,3,4,5, or 6 treatment- naïve and treatment -experienced with decompensated cirrhosis (Child-Pugh B and C)

24 weeks = Genotypes 1,2,3,4,5 or 6 treatment- naïve and treatment -experienced with decompensated cirrhosis (Child-Pugh B and C) and are ribavirin ineligible

1. What is the member's Genotype? _____

2. Is the member is 3 years if age or older with a diagnosis of chronic hepatitis C (CHC) infection with genotype 1, 2, 3, 4, 5 or genotype 6 without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis?

Yes No

3. As the provider, are you reasonably certain that treatment will improve the member's overall health status?

Yes No

4. Does the member have FDA labeled contraindications to Epclusa? Yes No

5. Is Epclusa is being used in combination with other drugs containing sofosbuvir? Yes No

Signature of Prescriber: _____ Date: _____

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.